Skip to content

Vivo Capital, LLC

Follow

13F filer, CIK 1674712, Palo Alto, CA

Vivo Capital, LLC reported $908,711,796 across 50 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13. Its ten largest share positions make up 51.28% of the portfolio.

Accepted , ingested 13F-HR 0001213900-26-119459

Period
2026-09-30
Reported value
$909M
Holdings
50
Top 10 weight
51.28%
New
8
Sold out
5

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ENTXnew+12,254,901$35.7M
KRSAnew+877,020$28.1M
BLSMnew+1,493,740$27.8M
VORnew+550,358$10.5M
CUEnew+280,057$7.25M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SVAexited-5,903,000-$38.2M
DNTHexited-353,998-$34.5M
DYNreduced-1,043,064-$16.8M
ORICreduced-924,394-$12.5M
TRVIreduced-864,985-$12.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001213900-26-119459, largest first. % of portfolio is the value over $908,711,796, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 167,600 shares; 2025Q3: 198,895 shares; 2025Q4: 328,895 shares; 2026Q1: 338,895 shares; 2026Q2: 271,116 shares; 2026Q3: 271,116 shares 271,116$79M8.69%0Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,487,903 shares; 2025Q1: 3,487,903 shares; 2025Q2: 4,487,903 shares; 2025Q3: 5,094,668 shares; 2025Q4: 5,094,668 shares; 2026Q1: 5,094,668 shares; 2026Q2: 5,094,668 shares; 2026Q3: 4,229,683 shares 4,229,683$60.6M6.67%-864,985Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,756,756 shares; 2025Q1: 6,756,756 shares; 2025Q2: 6,756,756 shares; 2025Q3: 9,273,428 shares; 2025Q4: 9,273,428 shares; 2026Q1: 12,151,480 shares; 2026Q2: 4,127,412 shares; 2026Q3: 4,020,619 shares 4,020,619$58.9M6.49%-106,793Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 885,916 shares; 2026Q2: 1,682,097 shares; 2026Q3: 1,787,104 shares 1,787,104$54.1M5.95%+105,007Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 359,305 shares; 2025Q4: 359,305 shares; 2026Q1: 239,539 shares; 2026Q2: 414,899 shares; 2026Q3: 414,899 shares 414,899$41.1M4.52%0Timeline
ENTXENTERA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 12,254,901 shares 12,254,901$35.7M3.92%newTimeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 8,888,888 shares; 2025Q1: 8,888,888 shares; 2025Q2: 8,888,888 shares; 2025Q3: 8,888,888 shares; 2025Q4: 8,888,888 shares; 2026Q1: 6,666,666 shares; 2026Q2: 6,694,637 shares; 2026Q3: 6,694,637 shares 6,694,637$35.2M3.88%0Timeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,035,551 shares; 2026Q1: 1,035,551 shares; 2026Q2: 1,208,858 shares; 2026Q3: 1,359,915 shares 1,359,915$34.7M3.82%+151,057Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 600,000 shares; 2025Q3: 776,699 shares; 2025Q4: 2,154,780 shares; 2026Q1: 2,154,780 shares; 2026Q2: 1,379,769 shares; 2026Q3: 1,379,769 shares 1,379,769$34.4M3.79%0Timeline
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,234,566 shares; 2025Q1: 2,234,566 shares; 2025Q2: 2,234,566 shares; 2025Q3: 2,234,566 shares; 2025Q4: 2,234,566 shares; 2026Q1: 2,805,816 shares; 2026Q2: 2,805,816 shares; 2026Q3: 2,805,816 shares 2,805,816$32.3M3.56%0Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 800,000 shares; 2025Q4: 800,000 shares; 2026Q1: 800,000 shares; 2026Q2: 800,000 shares; 2026Q3: 800,000 shares 800,000$30.7M3.38%0Timeline
KRSAKORSANA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 877,020 shares 877,020$28.1M3.09%newTimeline
BLSMBLOSSOMHILL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,493,740 shares 1,493,740$27.8M3.06%newTimeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 722,020 shares; 2026Q2: 722,020 shares; 2026Q3: 844,576 shares 844,576$25.1M2.76%+122,556Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 3,921,568 shares; 2025Q4: 4,246,568 shares; 2026Q1: 4,246,568 shares; 2026Q2: 4,246,568 shares; 2026Q3: 5,584,111 shares 5,584,111$22.6M2.48%+1,337,543Timeline
ACHVACHIEVE LIFE SCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,751,032 shares; 2026Q3: 2,751,032 shares 2,751,032$22.3M2.45%0Timeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 11,420,000 shares; 2025Q4: 11,420,000 shares; 2026Q1: 11,420,000 shares; 2026Q2: 7,299,909 shares; 2026Q3: 6,915,011 shares 6,915,011$21.9M2.41%-384,898Timeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 32,020 shares; 2025Q1: not reported; 2025Q2: 1,054,506 shares; 2025Q3: 1,054,506 shares; 2025Q4: 2,461,626 shares; 2026Q1: 2,667,569 shares; 2026Q2: 1,844,758 shares; 2026Q3: 1,844,758 shares 1,844,758$21.7M2.39%0Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 251,572 shares; 2025Q1: 251,572 shares; 2025Q2: 251,572 shares; 2025Q3: 501,617 shares; 2025Q4: 501,617 shares; 2026Q1: 557,172 shares; 2026Q2: 557,172 shares; 2026Q3: 417,879 shares 417,879$20.8M2.29%-139,293Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,612,903 shares; 2026Q1: 1,612,903 shares; 2026Q2: 1,612,903 shares; 2026Q3: 1,612,903 shares 1,612,903$20.3M2.23%0Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,153,640 shares; 2026Q2: 3,153,640 shares; 2026Q3: 3,153,640 shares 3,153,640$16.8M1.85%0Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,400,000 shares; 2026Q3: 1,400,000 shares 1,400,000$16.4M1.8%0Timeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 4,322,747 shares; 2026Q1: 4,322,747 shares; 2026Q2: 4,322,747 shares; 2026Q3: 4,322,747 shares 4,322,747$14.5M1.59%0Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 575,000 shares; 2026Q3: 575,000 shares 575,000$12.8M1.41%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,277,818 shares; 2025Q1: 2,080,450 shares; 2025Q2: 3,126,604 shares; 2025Q3: 3,126,604 shares; 2025Q4: 2,118,384 shares; 2026Q1: 1,848,786 shares; 2026Q2: 1,848,786 shares; 2026Q3: 924,392 shares 924,392$12.5M1.37%-924,394Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,350,000 shares; 2025Q4: 1,350,000 shares; 2026Q1: 1,350,000 shares; 2026Q2: 1,350,000 shares; 2026Q3: 1,350,000 shares 1,350,000$12.3M1.35%0Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 550,358 shares 550,358$10.5M1.16%newTimeline
EDITEDITAS MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,555,250 shares; 2026Q3: 3,555,250 shares 3,555,250$9.14M1.01%0Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 260,000 shares; 2025Q2: 260,000 shares; 2025Q3: 260,000 shares; 2025Q4: 260,000 shares; 2026Q1: 260,000 shares; 2026Q2: 260,000 shares; 2026Q3: 260,000 shares 260,000$8.37M0.92%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,114,960 shares; 2025Q1: 1,114,960 shares; 2025Q2: 1,114,960 shares; 2025Q3: 2,614,960 shares; 2025Q4: 2,614,960 shares; 2026Q1: 1,557,466 shares; 2026Q2: 1,557,466 shares; 2026Q3: 514,402 shares 514,402$8.29M0.91%-1,043,064Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,166,667 shares; 2026Q3: 1,166,667 shares 1,166,667$7.33M0.81%0Timeline
CUECUE BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 280,057 shares 280,057$7.25M0.8%newTimeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 90,500 shares; 2025Q4: 90,500 shares; 2026Q1: 90,500 shares; 2026Q2: 90,500 shares; 2026Q3: 90,500 shares 90,500$7.21M0.79%0Timeline
MSLESATELLOS BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 813,666 shares; 2026Q2: 813,666 shares; 2026Q3: 813,666 shares 813,666$6.92M0.76%0Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,505,862 shares; 2025Q1: 1,505,862 shares; 2025Q2: 1,505,862 shares; 2025Q3: 1,505,862 shares; 2025Q4: 671,843 shares; 2026Q1: 671,843 shares; 2026Q2: 671,843 shares; 2026Q3: 671,843 shares 671,843$5.8M0.64%0Timeline
PEPGPEPGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,325,000 shares; 2025Q4: 2,325,000 shares; 2026Q1: 2,325,000 shares; 2026Q2: 2,325,000 shares; 2026Q3: 2,325,000 shares 2,325,000$5.63M0.62%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,927,710 shares; 2026Q2: 1,927,710 shares; 2026Q3: 1,927,710 shares 1,927,710$5.25M0.58%0Timeline
ATTOATTOVIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 300,000 shares 300,000$5.14M0.57%newTimeline
ADRXADARX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 255,158 shares 255,158$5.09M0.56%newTimeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 208,333 shares; 2025Q1: 208,333 shares; 2025Q2: 208,333 shares; 2025Q3: 208,333 shares; 2025Q4: 208,333 shares; 2026Q1: 208,333 shares; 2026Q2: 2,500,000 shares; 2026Q3: 2,500,000 shares 2,500,000$4.72M0.52%0Timeline
VALNVALNEVA SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 763,199 shares; 2026Q3: 763,199 shares 763,199$4.72M0.52%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 275,000 shares; 2026Q3: 275,000 shares 275,000$4.22M0.46%0Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,556,023 shares; 2025Q1: 3,556,023 shares; 2025Q2: 6,043,466 shares; 2025Q3: 9,545,466 shares; 2025Q4: 9,545,466 shares; 2026Q1: 9,545,466 shares; 2026Q2: 7,757,060 shares; 2026Q3: 3,423,547 shares 3,423,547$3.56M0.39%-4,333,513Timeline
SERASERA PROGNOSTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,650,440 shares; 2025Q1: 1,650,440 shares; 2025Q2: 1,650,440 shares; 2025Q3: 1,650,440 shares; 2025Q4: 1,650,440 shares; 2026Q1: 1,650,440 shares; 2026Q2: 1,650,440 shares; 2026Q3: 1,650,440 shares 1,650,440$3.45M0.38%0Timeline
TILINSTIL BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 585,485 shares; 2025Q1: 585,485 shares; 2025Q2: 292,743 shares; 2025Q3: 292,743 shares; 2025Q4: 292,743 shares; 2026Q1: 292,743 shares; 2026Q2: 292,743 shares; 2026Q3: 292,743 shares 292,743$2.12M0.23%0Timeline
INMINMED PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 798,377 shares; 2026Q3: 824,874 shares 824,874$1.12M0.12%+26,497Timeline
BOLTBOLT BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 176,064 shares; 2025Q3: 176,064 shares; 2025Q4: 72,414 shares; 2026Q1: 72,414 shares; 2026Q2: 72,414 shares; 2026Q3: 72,414 shares 72,414$266K0.03%0Timeline
KTTAPASITHEA THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,100,000 shares; 2026Q1: 2,100,000 shares; 2026Q2: 465,471 shares; 2026Q3: 372,796 shares 372,796$184K0.02%-92,675Timeline
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,675 shares; 2025Q1: 4,675 shares; 2025Q2: 4,675 shares; 2025Q3: 4,675 shares; 2025Q4: 4,675 shares; 2026Q1: 4,675 shares; 2026Q2: 4,675 shares; 2026Q3: 4,675 shares 4,675$29.3K<0.01%0Timeline
JSPRJASPER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 5,364 shares 5,364$3.69K<0.01%newTimeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SVASINOVAC BIOTECH LTD5,903,000$38.2Mshares
DNTHDIANTHUS THERAPEUTICS INC353,998$34.5Mshares
GERNGERON CORP8,671,797$11.1Mshares
ALXOALX ONCOLOGY HLDGS INC3,184,713$6.59Mshares
UNCYUNICYCIVE THERAPEUTICS INC550,000$2.58Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001213900-26-119459 base2026-11-13